Introducing Provasctec: A Cell Therapy for Patients with Critical Limb Ischemia

ProVascTec, an NLC venture, will help patients with critical limb ischemia by triggering cell induced new vascular tissue growth.

Atherosclerosis describes the build-up of fats, cholesterol, and other substances within the inner arterial walls. This build-up, also called plaque, can cause arteries to narrow and eventually completely block arterial blood flow. If the occlusion is located in the patient’s limbs, the disease is referred to as peripheral arterial disease (PAD). Untreated PAD can progress to become critical limb ischemia (CLI). Typical symptoms of PAD include leg pain when walking, or claudication and decreased blood perfusion in the affected limbs. If PAD is not treated, it can progress to CLI with typical symptoms like rest pain, dying tissue from insufficient blood flow (gangrene), and non-healing open wounds (ulcers).

ProVascTec’s approach changes the treatment paradigm for CLI by going around the obstruction rather than through it. ProVascTec’s cell therapy is delivered via a proprietary device to generate a new vascular structure around the obstruction through the recruitment of local microvessels. ProVascTec will initially focus on applications below the knee, BTK, where no treatment is currently approved.

Dr. Holger Müller, CFA, CEO & Co-Founder of ProVascTec:

“Developing a novel treatment for patients who might otherwise face an amputation of all or part of their limbs is a true motivator to make this technology available”.

ProVascTec’s leadership team is completed by the inventor and co-founder, Prof. Dr. Noel Caplice, and Taco Van Der Feltz, NLC ventures. Prof. Caplice comes with 25 years of Clinician Scientist experience formerly at Mayo Clinic, Rochester, MN and now at University College Cork where he runs a translational lab in vascular biology. He is an academic interventional cardiologist, a serial inventor with multiple patents and a track record in translating bench concepts to first in man clinical trials. Noel will serve as Chief Scientific Officer. The project is currently in the preclinical stage.

For more information

ProVascTec: Website
Holger Müller, CFA - CEO & Co-Founder | Linkedin
info@provasctec.com